AnaptysBio shares surged 37% in premarket trading Wednesday after a mid-stage trial evaluating a rheumatoid arthritis treatment achieved its primary endpoint. Shares were recently trading around $17.
AnaptysBio (ANAB) announced statistically significant Week 12 data from the global 424-patient Phase 2b RENOIR trial of investigational ...
Investor's Business Daily on MSN40m
AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis TreatmentAnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.
AnaptysBio (ANAB) stock climbs as its antibody therapy rosnilimab meets key goals in mid-stage rheumatoid arthritis trial, ...
The positive trial results have not only demonstrated rosnilimab's potential in treating RA but have also validated AnaptysBio's scientific approach in targeting PD-1 co-inhibitory receptors on ...
Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.
SAN DIEGO - AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company currently trading near its 52-week low at $12.38, announced significant findings from their Phase 2b RENOIR trial for ...
SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor ...
Omega Therapeutics, Inc. OMGA gained 38.5% to $0.2678 in pre-market trading after jumping 79% on Tuesday. Omega Therapeutics ...
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback